Safety of Tofacitinib in the COVID-19 Pandemic-Enough Is Not Enough

Inflamm Bowel Dis. 2021 Jul 27;27(8):e89. doi: 10.1093/ibd/izab051.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • COVID-19*
  • Humans
  • Pandemics*
  • Piperidines
  • Pyrimidines / adverse effects
  • SARS-CoV-2

Substances

  • Piperidines
  • Pyrimidines
  • tofacitinib